MaFOS-GDM trial: Maternal fish oil supplementation in women with gestational diabetes and cord blood DNA methylation at insulin like growth factor-1 (IGF-1) gene

What Was Tested

This randomized controlled trial paper looks at IGF-1 LR3.

To evaluate the effects of maternal fish oil supplementation in women with gestational diabetes mellitus (GDM) on birthweight and DNA methylation at insulin like growth factor-1 (IGF-1) gene in their offspring.

Why It Was Studied

"Fish Oil Supplementation in Women with Gestational Diabetes".

Who Took Part

According to the abstract, 120 women were involved.

By PubMed's age tags, the people studied were adults, women only.

A total of 120 women with GDM were randomized to one of the two groups between 24 and 28 weeks of the pregnancy: Group 1 (n = 52) received fish oil liquid softgel (Ocean plus®) and Group 2 (Placebo) (n = 68) sunflower oil liquid softgel.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The women were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with IGF-1 LR3 could be set against what happens without it.

The birthweight and DNA methylation at IGF-1 gene of the offsprings were assessed.

What Was Measured

PubMed files the paper under topics including Biomarkers, Body Mass Index, DNA Methylation, Diabetes, Gestational, Dietary Supplements, Fetal Blood and Fish Oils.

Author keywords: Birthweight, Gestational diabetes and Insulin like growth factor.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of IGF-1 LR3 in 120 women.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Clinical nutrition ESPEN), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.